- Home
- BXP vs NBIX Comparison
BXP vs NBIX Comparison
Compare BXP & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXP
- NBIX
- Stock Information
- Founded
- BXP 1970
- NBIX 1992
- Country
- BXP United States
- NBIX United States
- Employees
- BXP N/A
- NBIX N/A
- Industry
- BXP Real Estate Investment Trusts
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BXP Real Estate
- NBIX Health Care
- Exchange
- BXP Nasdaq
- NBIX Nasdaq
- Market Cap
- BXP 10.4B
- NBIX 12.4B
- IPO Year
- BXP 1997
- NBIX 1996
- Fundamental
- Price
- BXP $68.95
- NBIX $132.02
- Analyst Decision
- BXP Buy
- NBIX Strong Buy
- Analyst Count
- BXP 15
- NBIX 21
- Target Price
- BXP $78.20
- NBIX $165.14
- AVG Volume (30 Days)
- BXP 1.7M
- NBIX 822.0K
- Earning Date
- BXP 07-29-2025
- NBIX 07-30-2025
- Dividend Yield
- BXP 5.67%
- NBIX N/A
- EPS Growth
- BXP N/A
- NBIX N/A
- EPS
- BXP N/A
- NBIX 2.96
- Revenue
- BXP $3,397,133,000.00
- NBIX $2,412,600,000.00
- Revenue This Year
- BXP $2.51
- NBIX $16.25
- Revenue Next Year
- BXP $2.86
- NBIX $15.23
- P/E Ratio
- BXP N/A
- NBIX $44.51
- Revenue Growth
- BXP 3.47
- NBIX 21.73
- 52 Week Low
- BXP $54.22
- NBIX $84.23
- 52 Week High
- BXP $90.11
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- BXP 47.93
- NBIX 57.42
- Support Level
- BXP $68.32
- NBIX $131.07
- Resistance Level
- BXP $71.70
- NBIX $135.70
- Average True Range (ATR)
- BXP 1.59
- NBIX 3.22
- MACD
- BXP -0.03
- NBIX -0.01
- Stochastic Oscillator
- BXP 47.12
- NBIX 60.94
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.